Karyopharm Therapeutics (KPTI) Free Cash Flow (2012 - 2025)
Karyopharm Therapeutics' (KPTI) quarterly Free Cash Flow came in at -$11.8 million in Q4 2025, up 54.08% YoY from -$7.7 million in Q4 2024, and down 101.84% on a QoQ basis from -$5.9 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Free Cash Flow (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Free Cash Flow data on file, last reported at -$11.8 million in Q4 2025.
- Quarterly Free Cash Flow rose 54.08% year-over-year to -$11.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$75.4 million (up 40.95% YoY) and the FY2025 annual result came in at -$75.4 million, up 40.95% from the prior year.
- Free Cash Flow slipped to -$11.8 million in Q4 2025, from -$5.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $25.3 million in Q4 2021 to a low of -$59.3 million in Q1 2022.
- A 5-year average of -$27.6 million and a median of -$26.3 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2021 — Free Cash Flow jumped 182.16% — and 2022, when it sank 206.23%.
- Tracing KPTI's Free Cash Flow over 5 years: stood at $25.3 million in 2021, then slumped by 206.23% to -$26.8 million in 2022, then soared by 30.76% to -$18.6 million in 2023, then sank by 38.59% to -$25.8 million in 2024, then soared by 54.08% to -$11.8 million in 2025.
- The last three Free Cash Flow figures came in at -$11.8 million (Q4 2025), -$5.9 million (Q3 2025), and -$18.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.83 Mn |
| Dec 31, 2025 | -11.83 Mn |
| Sep 30, 2025 | -5.86 Mn |
| Sep 30, 2025 | -5.86 Mn |
| Jun 30, 2025 | -18.70 Mn |
| Jun 30, 2025 | -18.70 Mn |
| Mar 31, 2025 | -38.98 Mn |
| Mar 31, 2025 | -38.98 Mn |
| Dec 31, 2024 | -25.76 Mn |
| Dec 31, 2024 | -25.76 Mn |
| Sep 30, 2024 | -19.45 Mn |
| Sep 30, 2024 | -19.45 Mn |
| Jun 30, 2024 | -38.50 Mn |
| Jun 30, 2024 | -38.50 Mn |
| Mar 31, 2024 | -43.92 Mn |
| Mar 31, 2024 | -43.92 Mn |
| Dec 31, 2023 | -18.59 Mn |
| Dec 31, 2023 | -18.59 Mn |
| Sep 30, 2023 | -29.53 Mn |
| Sep 30, 2023 | -29.53 Mn |